Video Feed

3D MOA Animation video

OncoSec's VLA 3D MOA Animation

TAVO Demonstration with Dr Algazi

OncoSec at 2020 BIO CEO Panel

Tumor Immunogenicity

IAD Reel

IAD Robert Andtbacka, M.D.

Social Media

Twitter Feed

Our #DNA gene transfer technology is being studied in pivotal Phase II trials in #MetastaticMelanoma. Recent results have demonstrated a local #Immune response as either a #Monotherapy or a #CombinationTreatment approach. Learn more here:

#DYK most solid tumors treated with anti-PD-1/PD-L1 therapies do not respond to treatment? This is one of the greatest challenges in #Oncology today. Our Phase II results are pacing the way for the growth of our #ImmunoOncology #Pipeline. Learn more:

This July, join us in recognizing #UVSafetyAwarenessMonth by taking the right precautions to enjoy the sun & outdoors this #summer while protecting yourself to #PreventCancer. Learn more about ways you can minimize the risk that comes with sun exposure:

We are pleased to announce that we have entered into a collaboration agreement with @Merck for a pivotal global #Phase3 study, KEYNOTE-687 for late-stage #MetastaticMelanoma. Learn more here: